Hayes News

Hayes News Service keeps our clients up to date with late-breaking news from clinical trials, coverage decisions, and new product approvals. We focus on emerging technologies with potentially high clinical and financial impact as soon as they are announced publicly.

Our analysts scan more than 75 peer-reviewed journals and news briefings from government agencies, medical associations, and research institutes. Results of selected studies or articles are summarized and posted with a brief commentary on whether the findings are likely to have a substantial impact.

    Market Withdrawal: Rubraca for Third-Line Ovarian Cancer Indication

    Clovis Oncology Inc. has announced a voluntary market withdrawal of Rubraca (rucaparib) in the U.S. as treatment of BRCA-mutated ovarian cancer after 2 or more chemotherapies. This withdrawal became effective on June 10, 2022, and does not affect other indications for Rubraca.

    FDA Update on Philips Respironics Recall

    The U.S. Food and Drug Administration (FDA) has updated a safety communication on certain Philips Respironics ventilators, BiPAP machines, and CPAP machines that were recalled due to potential health risks.

    FDA News Alerts

    The U.S. Food and Drug Administration (FDA) recently posted these news items.